|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US5981216A
(en)
|
1985-04-01 |
1999-11-09 |
Alusuisse Holdings A.G. |
Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
|
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
GB8717430D0
(en)
|
1987-07-23 |
1987-08-26 |
Celltech Ltd |
Recombinant dna product
|
|
JP3039802B2
(ja)
|
1989-07-06 |
2000-05-08 |
ザ リージェンツ オブザ ユニバーシティ オブ カリフォルニア |
繊維芽細胞成長因子のための受容体
|
|
US5863888A
(en)
|
1990-07-06 |
1999-01-26 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Human Bek Fibroblast growth factor receptor
|
|
EP0940468A1
(en)
|
1991-06-14 |
1999-09-08 |
Genentech, Inc. |
Humanized antibody variable domain
|
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
|
US6323316B1
(en)
|
1996-06-18 |
2001-11-27 |
The United States Of America As Represented By The Secretary Of The Department Of And Human Services |
Fibroblast growth factor receptor activating gene 1 and related compositions and methods
|
|
JP2002506353A
(ja)
|
1997-06-24 |
2002-02-26 |
ジェネンテック・インコーポレーテッド |
ガラクトシル化糖タンパク質の方法及び組成物
|
|
WO1999022764A1
(en)
|
1997-10-31 |
1999-05-14 |
Genentech, Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
|
BR9813365A
(pt)
|
1997-12-05 |
2004-06-15 |
Scripps Research Inst |
Método para produção e humanização de um anticorpo monoclonal de rato
|
|
PT1068241E
(pt)
|
1998-04-02 |
2007-11-19 |
Genentech Inc |
Variantes de anticorpos e respectivos fragmentos
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US20030175884A1
(en)
|
2001-08-03 |
2003-09-18 |
Pablo Umana |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
|
DK1071700T3
(da)
|
1998-04-20 |
2010-06-07 |
Glycart Biotechnology Ag |
Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
|
|
WO2000025803A1
(en)
|
1998-10-30 |
2000-05-11 |
Takeda Chemical Industries, Ltd. |
Betacellulin protein-containing preparations
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
AU3672800A
(en)
|
1999-04-09 |
2000-11-14 |
Kyowa Hakko Kogyo Co. Ltd. |
Method for controlling the activity of immunologically functional molecule
|
|
WO2000064946A2
(en)
|
1999-04-28 |
2000-11-02 |
Board Of Regents, The University Of Texas System |
Compositions and methods for cancer treatment by selectively inhibiting vegf
|
|
EP1229125A4
(en)
|
1999-10-19 |
2005-06-01 |
Kyowa Hakko Kogyo Kk |
PROCESS FOR PREPARING A POLYPEPTIDE
|
|
JP2001302699A
(ja)
|
2000-04-17 |
2001-10-31 |
Nichirei Corp |
ヒトｋｇｆｒに対する抗体
|
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
|
HU231090B1
(hu)
|
2000-10-06 |
2020-07-28 |
Kyowa Kirin Co., Ltd. |
Antitest-kompozíciót termelő sejt
|
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
AU2002314495A1
(en)
|
2001-06-20 |
2003-01-02 |
Prochon Biotech Ltd. |
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
|
ATE430580T1
(de)
|
2001-10-25 |
2009-05-15 |
Genentech Inc |
Glycoprotein-zusammensetzungen
|
|
CN101357943A
(zh)
*
|
2001-10-25 |
2009-02-04 |
杰南技术公司 |
糖蛋白组合物
|
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
|
DE60336452D1
(de)
|
2002-01-31 |
2011-05-05 |
Max Planck Gesellschaft |
Fgfr agoniste
|
|
US8093357B2
(en)
*
|
2002-03-01 |
2012-01-10 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US20040132101A1
(en)
*
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
JP4832719B2
(ja)
|
2002-04-09 |
2011-12-07 |
協和発酵キリン株式会社 |
ＦｃγＲＩＩＩａ多型患者に適応する抗体組成物含有医薬
|
|
WO2003085102A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
|
|
CA2481837A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Production process for antibody composition
|
|
WO2003084569A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Drug containing antibody composition
|
|
EP1498491A4
(en)
|
2002-04-09 |
2006-12-13 |
Kyowa Hakko Kogyo Kk |
METHOD FOR ENHANCING ACTIVITY OF BINDING ANTIBODY COMPOSITION WITH FC GAMMA IIIA RECEPTOR
|
|
EP1498485A4
(en)
|
2002-04-09 |
2006-09-06 |
Kyowa Hakko Kogyo Kk |
MODIFIED GENOME CELLS
|
|
KR100493460B1
(ko)
|
2002-08-29 |
2005-06-07 |
재단법인서울대학교산학협력재단 |
암 세포에서 발현되는 ｆｇｆｒ2 이성체
|
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
CN103833854B
(zh)
|
2002-12-16 |
2017-12-12 |
健泰科生物技术公司 |
免疫球蛋白变体及其用途
|
|
CA2766627C
(en)
*
|
2003-05-02 |
2019-12-03 |
Xencor, Inc. |
Optimized fc variants and methods for their generation
|
|
CA2542046A1
(en)
|
2003-10-08 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
Fused protein composition
|
|
EP1705251A4
(en)
|
2003-10-09 |
2009-10-28 |
Kyowa Hakko Kirin Co Ltd |
PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY RNA INHIBITION OF FUNCTION OF $ G (A) 1,6-FUCOSYLTRANSFERASE
|
|
PL1680140T3
(pl)
*
|
2003-10-16 |
2011-11-30 |
Imclone Llc |
Inhibitory receptora-1 czynnika wzrostu fibroblastów i związane z nim sposoby leczenia
|
|
WO2005040395A1
(en)
|
2003-10-22 |
2005-05-06 |
Keck Graduate Institute |
Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
|
|
BRPI0416262B1
(pt)
|
2003-11-05 |
2022-04-12 |
Roche Glycart Ag |
Anticorpo anti-cd20 humano tipo ii humanizado, seu método de produção, seus usos, bem como polinucleotídeo isolado, vetor de expressão e composição farmacêutica
|
|
JPWO2005053742A1
(ja)
|
2003-12-04 |
2007-06-28 |
協和醗酵工業株式会社 |
抗体組成物を含有する医薬
|
|
EP1697420A2
(en)
|
2003-12-19 |
2006-09-06 |
Five Prime Therapeutics, Inc. |
Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
|
|
MXPA06011199A
(es)
|
2004-03-31 |
2007-04-16 |
Genentech Inc |
Anticuerpos anti-tgf-beta humanizados.
|
|
EP1773305A2
(en)
|
2004-05-25 |
2007-04-18 |
Yale University Corporation |
Method for treating skeletal disorders resulting from fgfr malfunction
|
|
ATE454455T1
(de)
|
2005-01-27 |
2010-01-15 |
Five Prime Therapeutics Inc |
Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung
|
|
JP2008530244A
(ja)
*
|
2005-02-18 |
2008-08-07 |
メダレックス， インク． |
フコシル残基を欠くｃｄ３０に対するモノクローナル抗体
|
|
US7923538B2
(en)
|
2005-07-22 |
2011-04-12 |
Kyowa Hakko Kirin Co., Ltd |
Recombinant antibody composition
|
|
EP2041575A2
(en)
|
2006-03-31 |
2009-04-01 |
Ordway Research Institute |
Prognostic and diagnostic method for cancer therapy
|
|
WO2007134210A2
(en)
|
2006-05-12 |
2007-11-22 |
Genentech, Inc. |
Methods and compositions for the diagnosis and treatment of cancer
|
|
CA2655246A1
(en)
*
|
2006-06-09 |
2007-12-21 |
University Of Maryland, Baltimore |
Glycosylation engineered antibody therapy
|
|
CA2655504A1
(en)
|
2006-06-15 |
2007-12-21 |
Fibron Ltd. |
Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
|
|
AR062223A1
(es)
|
2006-08-09 |
2008-10-22 |
Glycart Biotechnology Ag |
Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
|
|
EA018260B1
(ru)
|
2006-09-29 |
2013-06-28 |
Онкомед Фармасьютикалз, Инк. |
Антитела к дельта-подобному лиганду 4 человека и их применение
|
|
CA2668295A1
(en)
|
2006-11-03 |
2008-05-08 |
U3 Pharma Gmbh |
Fgfr4 antibodies
|
|
CL2007003411A1
(es)
|
2006-11-28 |
2008-07-04 |
Centelion |
Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu
|
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
|
TW200833711A
(en)
|
2006-12-22 |
2008-08-16 |
Genentech Inc |
Antibodies to insulin-like growth factor receptor
|
|
EP2119780B1
(en)
|
2007-01-24 |
2015-03-25 |
Kyowa Hakko Kirin Co., Ltd. |
Genetically recombinant antibody composition having enhanced effector activity
|
|
CA2680046A1
(en)
|
2007-03-23 |
2008-10-02 |
The Translational Genomics Research Institute |
Methods of diagnosing, classifying and treating endometrial cancer and precancer
|
|
US20130183288A1
(en)
*
|
2007-03-28 |
2013-07-18 |
Biogen Idec Inc. |
Non-fucosylated antibodies
|
|
WO2009052830A1
(en)
|
2007-10-22 |
2009-04-30 |
Genmab A/S |
Novel antibody therapies
|
|
US20110059091A1
(en)
|
2008-02-04 |
2011-03-10 |
Xiao-Jia Chang |
Inhibitors of oncogenic isoforms and uses thereof
|
|
US9260525B2
(en)
|
2008-02-04 |
2016-02-16 |
Xiao-Jia Chang |
Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
|
|
US8688158B2
(en)
|
2008-03-26 |
2014-04-01 |
Nec Corporation |
Radio resource control method, radio station apparatus, recording medium storing radio station control program, and radio communication system
|
|
CA2727247A1
(en)
*
|
2008-06-10 |
2009-12-17 |
University Of Southern California |
Thymidylate synthase haplotype is associated with tumor recurrence in stage ii and stage iii colon cancer patients
|
|
EP2177615A1
(en)
|
2008-10-10 |
2010-04-21 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
|
|
MX2011000455A
(es)
|
2008-11-07 |
2011-02-25 |
Galaxy Biotech Llc |
Anticuerpos monoclonales especificos al receptor 2 del factor de crecimiento de fibroblastos.
|
|
WO2011025814A1
(en)
|
2009-08-25 |
2011-03-03 |
National Jewish Health |
Methods and compositions for treatment of lung injury
|
|
JP5898082B2
(ja)
*
|
2009-10-07 |
2016-04-06 |
マクロジェニクス，インコーポレーテッド |
フコシル化程度の変更により改良されたエフェクター機能を示すＦｃ領域含有ポリペプチドおよびその使用法
|
|
JP2013508292A
(ja)
*
|
2009-10-14 |
2013-03-07 |
カロバイオス ファーマシューティカルズ インコーポレイティッド |
ＥｐｈＡ３に対する抗体
|
|
US20120328599A1
(en)
|
2010-01-14 |
2012-12-27 |
Yale University |
Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof
|
|
US9140689B2
(en)
|
2010-03-14 |
2015-09-22 |
Translational Genomics Research Institute |
Methods of determining susceptibility of tumors to tyrosine kinase inhibitors
|
|
RU2012153241A
(ru)
*
|
2010-05-11 |
2014-06-20 |
Авео Фармасьютикалз, Инк. |
Антитела к fgfr2
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
EP2603521A4
(en)
|
2010-08-12 |
2014-10-01 |
Attogen Inc |
ANTIBODY MOLECULARS FOR ONGOGEN FIBROBLAST GROWTH RECEPTOR 2 ISOFORMS AND ITS USES
|
|
US20120258496A1
(en)
*
|
2010-09-27 |
2012-10-11 |
Boehringer Ingelheim International Gmbh |
Production of low fucose antibodies in h4-ii-e rat cells
|
|
EP3828205A1
(en)
*
|
2010-10-01 |
2021-06-02 |
Oxford BioTherapeutics Ltd |
Anti-ror1 antibodies
|
|
DK2714738T3
(en)
|
2011-05-24 |
2019-01-28 |
Zyngenia Inc |
MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
|
|
AR088941A1
(es)
|
2011-11-23 |
2014-07-16 |
Bayer Ip Gmbh |
Anticuerpos anti-fgfr2 y sus usos
|
|
MX2014007121A
(es)
|
2011-12-14 |
2014-09-04 |
Seattle Genetics Inc |
Nuevos conjugados de principio activo-ligante (adc) y su uso.
|
|
PT2831110T
(pt)
*
|
2012-03-30 |
2018-09-28 |
Univ California |
Terapia anti-emp2 reduz as células-tronco do cancro
|
|
SG11201406422TA
(en)
|
2012-04-09 |
2014-11-27 |
Daiichi Sankyo Co Ltd |
Anti-fgfr2 antibody
|
|
US9254288B2
(en)
|
2012-05-07 |
2016-02-09 |
The Translational Genomics Research Institute |
Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
|
|
KR102702287B1
(ko)
|
2012-05-15 |
2024-09-04 |
브리스톨-마이어스 스큅 컴퍼니 |
Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법
|
|
EP2871236A4
(en)
|
2012-07-05 |
2016-03-09 |
Nat Cancer Ct |
FGFR2 fusion
|
|
WO2014089193A1
(en)
|
2012-12-04 |
2014-06-12 |
Aveo Pharmaceuticals, Inc. |
Anti-fgfr2 antibodies
|
|
EP3939614A1
(en)
|
2013-01-18 |
2022-01-19 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
|
US9415118B2
(en)
|
2013-03-13 |
2016-08-16 |
Novartis Ag |
Antibody drug conjugates
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
WO2014179448A2
(en)
|
2013-05-01 |
2014-11-06 |
Five Prime Therapeutics, Inc. |
Methods of treating cancer
|
|
SG11201510210XA
(en)
|
2013-06-13 |
2016-01-28 |
Univ South Australia |
Methods for detecting prostate cancer
|
|
RS58719B1
(sr)
|
2013-08-01 |
2019-06-28 |
Five Prime Therapeutics Inc |
Nefukozilisana anti-fgfr2iiib antitela
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
AU2015210886A1
(en)
|
2014-01-29 |
2016-09-01 |
Caris Mpi, Inc. |
Molecular profiling of immune modulators
|
|
CA2961439A1
(en)
|
2014-11-05 |
2016-05-12 |
Genentech, Inc. |
Anti-fgfr2/3 antibodies and methods using same
|
|
US20170340733A1
(en)
|
2014-12-19 |
2017-11-30 |
Novartis Ag |
Combination therapies
|
|
US10478494B2
(en)
|
2015-04-03 |
2019-11-19 |
Astex Therapeutics Ltd |
FGFR/PD-1 combination therapy for the treatment of cancer
|
|
CN108368174B
(zh)
|
2015-11-23 |
2023-04-14 |
戊瑞治疗有限公司 |
用于癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合
|
|
US11091555B2
(en)
|
2017-05-16 |
2021-08-17 |
Five Prime Therapeutics, Inc. |
Method of treating gastric cancer with anti-FGFR2-IIIb antibodies and modified FOLFOX6 chemotherapy
|